191 related articles for article (PubMed ID: 38100899)
21. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.
Mooradian MJ; Nasrallah M; Gainor JF; Reynolds KL; Cohen JV; Lawrence DP; Miloslavsky EM; Kohler MJ; Sullivan RJ; Schoenfeld SR
Semin Arthritis Rheum; 2019 Jun; 48(6):1127-1132. PubMed ID: 30409415
[TBL] [Abstract][Full Text] [Related]
22. Improved flare and remission pattern in rheumatoid arthritis over recent decades: a population-based study.
Raheel S; Matteson EL; Crowson CS; Myasoedova E
Rheumatology (Oxford); 2017 Dec; 56(12):2154-2161. PubMed ID: 28968703
[TBL] [Abstract][Full Text] [Related]
23. Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study.
Emery P; Burmester GR; Naredo E; Sinigaglia L; Lagunes I; Koenigsbauer F; Conaghan PG
Ann Rheum Dis; 2020 Aug; 79(8):1023-1030. PubMed ID: 32404343
[TBL] [Abstract][Full Text] [Related]
24. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
[TBL] [Abstract][Full Text] [Related]
25. Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis?
Scott IC; Kingsley GH; Scott DL
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S4-8. PubMed ID: 24129128
[TBL] [Abstract][Full Text] [Related]
26. Validation and predictive capacity of a Dutch version of the FLARE-RA questionnaire within the context of a TNFi-tapering trial.
Doumen M; Bertrand D; Pazmino S; De Cock D; Stouten V; Joly J; de Wergifosse I; Moeyersoons A; Westhovens R; Verschueren P
Clin Rheumatol; 2023 Jan; 42(1):39-45. PubMed ID: 35943667
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcomes after discontinuing biological drugs and tofacitinib in patients with rheumatoid arthritis: A prospective cohort study.
Mori S; Okada A; Koga T; Ueki Y
PLoS One; 2022; 17(6):e0270391. PubMed ID: 35737642
[TBL] [Abstract][Full Text] [Related]
28. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
[TBL] [Abstract][Full Text] [Related]
29. Risk factors of flare in rheumatoid arthritis patients with both clinical and ultrasonographic remission: a retrospective study from China.
Han J; Geng Y; Deng X; Zhang Z
Clin Rheumatol; 2017 Aug; 36(8):1721-1727. PubMed ID: 28639002
[TBL] [Abstract][Full Text] [Related]
30. Baseline predictors of disease severity in immune checkpoint inhibitor-induced inflammatory arthritis.
Cappelli LC; Kamal O; Jones M; Bingham CO; Shah AA
Rheumatology (Oxford); 2024 May; 63(6):1518-1522. PubMed ID: 37647635
[TBL] [Abstract][Full Text] [Related]
31. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
[TBL] [Abstract][Full Text] [Related]
32. Predictors of flare in rheumatoid arthritis patients with persistent clinical remission/low disease activity: Data from the TARAC cohort.
Chaiamnuay S; Jiemjit S; Songdechaphipat W; Narongroeknawin P; Pakchotanon R; Asavatanabodee P
Medicine (Baltimore); 2022 Aug; 101(32):e29974. PubMed ID: 35960097
[TBL] [Abstract][Full Text] [Related]
33. Prediction of flare following glucocorticoids withdrawal in rheumatoid arthritis patients with continuation of csDMARDs: a real-life study.
Xie W; Huang H; Zhang Z
Intern Emerg Med; 2023 Sep; 18(6):1759-1767. PubMed ID: 37418144
[TBL] [Abstract][Full Text] [Related]
34. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
Ozen G; Pedro S; Holmqvist ME; Avery M; Wolfe F; Michaud K
Ann Rheum Dis; 2017 May; 76(5):848-854. PubMed ID: 27836820
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and factors associated with flares following COVID-19 mRNA vaccination in patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: a national cohort study.
Fong W; Woon TH; Chew LC; Low A; Law A; Poh YJ; Yeo SI; Leung YY; Ma M; Santosa A; Kong KO; Xu C; Teng GG; Mak A; Tay SH; Chuah TY; Roslan NE; Angkodjojo S; Phang KF; Sriranganathan M; Tan TC; Cheung P; Lahiri M
Adv Rheumatol; 2023 Aug; 63(1):38. PubMed ID: 37528453
[TBL] [Abstract][Full Text] [Related]
36. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
37. Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis.
Bass AR; Abdel-Wahab N; Reid PD; Sparks JA; Calabrese C; Jannat-Khah DP; Ghosh N; Rajesh D; Aude CA; Gedmintas L; MacFarlane L; Arabelovic S; Falohun A; Mushtaq K; Haj FA; Diab A; Shah AA; Bingham CO; Chan KK; Cappelli LC
Ann Rheum Dis; 2023 Jul; 82(7):920-926. PubMed ID: 37019614
[TBL] [Abstract][Full Text] [Related]
38. Pain and Self-reported Swollen Joints Are Main Drivers of Patient-reported Flares in Rheumatoid Arthritis: Results from a 12-month Observational Study.
Kuettel D; Primdahl J; Weber U; Terslev L; Østergaard M; Petersen R; Pedersen AK; Möller S; Hørslev-Petersen K
J Rheumatol; 2020 Sep; 47(9):1305-1313. PubMed ID: 31787604
[TBL] [Abstract][Full Text] [Related]
39. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics associated with drug-free sustained remission in patients with rheumatoid arthritis: Data from Korean Intensive Management of Early Rheumatoid Arthritis (KIMERA).
Jung SM; Pyo JY; Lee SW; Song JJ; Lee SK; Park YB
Semin Arthritis Rheum; 2020 Dec; 50(6):1414-1420. PubMed ID: 32241617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
